Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

This Phase 3 study is comparing a new weekly injectable medication called GZR18 to the approved weight-loss drug semaglutide (Wegovy) in Chinese adults who are overweight or obese, to determine whether GZR18 is similarly effective and safe. The study includes participants both with and without type 2 diabetes who have a BMI of 24 or higher with weight-related health conditions. You may be eligible if you are 18 or older, have not had significant weight changes in the past 3 months, have not previously used GLP-1 receptor agonist medications, and meet BMI and weight-related health condition criteria for your diabetes status. Participation involves weekly self-administered injections, regular clinic visits for blood tests and measurements, and following diet and exercise recommendations throughout the trial. This summary was prepared using AI to help patients understand this research.